Kynurenine metabolism processes may be a promising target to restore tumor-restraining T-cell immunogenicity and therefore promote ICB therapeutic efficacy in gastric cancer, such as IDO1 inhibitor.58 We observed that glycogen metabolism was significantly activated in low TMEscore tumors and immune exclusive molecular subtypes both in TCGA-STAD cohort and ACRG cohort (figure 5D and online supplemental figure S10A–F), which suggest that it may be correlated with immune exclusion phenotype (figure 5E and online supplemental figure S10G, H) and mediate treatment resistance of immunotherapy. This evidence concerns the gene IDO1 and gastric cancer.